KNSA Kiniksa Pharmaceuticals, Ltd.

NASDAQ
$75.08

Kiniksa Pharmaceuticals, Ltd. (KNSA) is expected to report earnings on October 30, 2026, before the market open. The consensus earnings estimate is $0.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.2% since its last earnings release on July 28, 2026.

Kiniksa Pharmaceuticals, Reported In-line with Estimates, Raises Guidance
Tuesday, July 28, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 30
Friday · 7:30 AM ET
Earnings Whisper
-
vs $0.39
Rev est $259.52M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $78.10

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kiniksa Pharmaceuticals, Ltd.

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.